Life Sciences Tools and Services

GEMPHARMATECH

GEMPHARMATECH released FY2026 Q1 earnings on April 22 After-Market (BJT), actual revenue CNY 208.08 M, actual EPS CNY 0.12

GEMPHARMATECH to Release FY2026 Q1 Earnings on April 23 After-Market BJT

GEMPHARMATECH to release FY2025 earnings on April 23 Pre-Market (BJT), forecast revenue CNY 788.32 M, EPS CNY 0.3066

GEMPHARMATECH released FY2025 earnings on February 3 Pre-Market (BJT), actual revenue CNY 793.39 M (forecast CNY 788.32 M), actual EPS CNY 0.35 (forecast CNY 0.3066)

GEMPHARMATECH released FY2025 Q4 earnings on February 3, Pre-Market (BJT), with actual revenue of CNY 217.81 M and EPS of CNY 0.08

GEMPHARMATECH released FY2025 9 Months Earnings on October 22 After-Market (BJT), actual revenue CNY 575.58 M, actual EPS CNY 0.2716

GEMPHARMATECH released FY2025 Q3 earnings on October 22 After-Market (BJT), actual revenue CNY 200.77 M, actual EPS CNY 0.1007

GEMPHARMATECH FY2025 Q3 Earnings Release on October 23, After-Market (BJT)

GEMPHARMATECH released FY2025 Semi-Annual Earnings on August 22 After-Market (BJT), Actual Revenue: CNY 374.81 M, Actual EPS: CNY 0.17

GEMPHARMATECH released FY2025 Q2 earnings on August 22 After-Market BJT, actual revenue CNY 203.95 M, actual EPS CNY 0.1008

GEMPHARMATECH to Release FY2025 Semi-Annual Earnings on August 23, 2025 (BJT)

Pharmkind Biotech's stock up 12.07%, rated buy by Orient Securities

PharmaModel Adds New Investment Project to Layout Organoids

FDA Releases Roadmap to Reduce Animal Testing

GEMPHARMATECH released FY2025 Q1 earnings on April 25 During-Market (BJT), actual revenue CNY 170.86 M, actual EPS CNY 0.07

GEMPHARMATECH to Release FY2025 Q1 Earnings Report on April 26 During-Market BJT

GEMPHARMATECH to release FY2024 earnings on April 26 After-Market (BJT), forecast revenue CNY 731 M, EPS CNY 0.395

PharmaKang Bio Establishes a Biotech Center in San Diego, USA

GEMPHARMATECH released FY2024 annual earnings on February 27 After-Market BJT, actual revenue CNY 686.84 M (forecast CNY 731 M), actual EPS CNY 0.27 (forecast CNY 0.395)

GEMPHARMATECH released FY2024 Q4 earnings on February 27 After-Market BJT, actual revenue CNY 177.12 M, actual EPS CNY 0.029

688046

According to the Zhitong Finance APP, GEMPHARMATECH disclosed its third-quarter report for 2025. The company achieved revenue of 576 million yuan in the first three quarters, a year-on-year increase of 12.92%; the net profit attributable to shareholders of the listed company was 110 million yuan, a year-on-year increase of 11.9%; the net profit excluding non-recurring gains and losses was 92.79 million yuan, a year-on-year increase of 29.21%; the basic earnings per share were 0.27 yuan

Zhitong

GEMPHARMATECH released its performance for the first three quarters, with a net profit attributable to the parent company of 110 million yuan, a year-on-year increase of 11.9%

In the first half of 2025, GEMPHARMATECH's operating revenue was 375 million yuan, a year-on-year increase of 10.11%; net profit was 70.9055 million yuan, a year-on-year decrease of 7.12%. The company plans to distribute a cash dividend of 0.3 yuan for every 10 shares based on the total share capital registered on the equity distribution registration date, totaling 12.2697 million yuan, accounting for 17.30% of the net profit

GEMPHARMATECH: Net profit in the first half of 2025 was 70.9055 million yuan, a year-on-year decrease of 7.12%

603127

06127

688073

300347

03347

688131

688621

The CRO sector rose, with JOINN up 8.94%, GEMPHARMATECH up 7.3%, Bide up 6.7%, and TIGERMED, Chemexpress, and Sun-Novo all rising over 5%

JOINN

Bide

Tigermed

TIGERMED

Chemexpress

Sun-Novo

605566

603583

002694

688255

On April 25th, a total of 5 listed companies had their restricted shares unlocked, with a total market value of approximately 5.599 billion yuan. The specific situation of the restricted share unlock today is as follows: Stock Abbreviation Stock Code Restricted Share Type Unlock Shares Guody Technology 002694 Additional A Shares Legal Person Allocation Listed 166 million Jiecang Linear Motion Technology 603583 Equity Incentive Restricted Circulation 237,500 FLARIANT 605566 Extended Restricted Lock-up Period Circulation 71.052 million Kaierda 688255 39.97563 million GEMPHARMATECH 688046 6.206 billion

FLARIANT

Jiecang Linear Motion Technology

GOODY

Kaierda

Overview of the lifting of restrictions on A-shares by Zhitong | April 25

A state-of-the-art laboratory and rodent vivarium facility has been established in North America to bolster preclinical research capabilities. GemPharmatech, a prominent provider of genetically engineered mouse models and preclinical contract research services, unveiled this facility in San Diego on April 17, 2025. The facility aims to enhance research infrastructure and support innovative studies in the region.

Unusual Whales

GemPharmatech opens new biotech hub in San Diego, boosting research capabilities with lab and vivarium.

GemPharmatech has opened a new facility in San Diego, enhancing its U.S. capabilities in genetically engineered mouse models and preclinical research. This expansion supports North American biomedical research and pharmaceutical development, featuring a state-of-the-art rodent vivarium and laboratory space. The facility aims to provide faster turnaround times and improved project coordination for U.S.-based researchers, while maintaining high standards of animal welfare and data quality. This move reflects GemPharmatech's commitment to advancing biomedical research and therapeutic development.

biopharmadive

GemPharmatech Significantly Expands U.S.  Capabilities with New San Diego Biotech Hub Facility

According to the Zhitong Finance APP, GEMPHARMATECH announced that the restricted shares for this listing are held by some shareholders prior to the company's initial public offering, involving 4 shareholders, with a total of approximately 206 million shares, accounting for 50.2607% of the company's total shares. The lock-up period is 36 months from the date of the company's stock listing, and the restrictions will be lifted and the shares will be listed for trading on April 25, 2025

GEMPHARMATECH's approximately 206 million restricted shares will be listed and circulated on April 25

GEMPHARMATECH is accelerating its internationalization strategy, expanding into overseas markets, and building a sales network covering the Asia-Pacific, Europe, and the United States. The company's overseas business mainly revolves around the delivery of efficacy reports, which is less affected by "countervailing tariffs." GEMPHARMATECH is also actively constructing overseas facilities to enhance market competitiveness and respond to market risks, laying a foundation for long-term development

GEMPHARMATECH: Overseas business focuses on the delivery of efficacy reports, "reciprocal tariffs" have little impact on the company

GEMPHARMATECH announced a draft employee stock ownership plan for 2025, planning to hold approximately 2.04 million shares, accounting for about 0.50% of the company's total share capital. The stock purchase price is RMB 7.12 per share, with no more than 45 participants, and a duration of 36 months

GEMPHARMATECH plans to launch an employee stock ownership plan in 2025

GEMPHARMATECH announced the draft of its 2025 stock appreciation rights incentive plan, proposing to grant 546,000 stock appreciation rights, accounting for 0.13% of the company's total share capital. The exercise price is set at RMB 7.12 per share, involving 27 incentive recipients, including senior management and key personnel. The incentive plan has a maximum validity period of 36 months, with the exercise divided into two phases, each accounting for 50%

GEMPHARMATECH plans to launch a stock appreciation rights incentive plan in 2025

GEMPHARMATECH(688046.SH)